Osteonecrosis of the jaw as a result of bisphosphonate therapy for osteoporosis and the success of dental implantation – a review of current scientific evidence
DOI:
https://doi.org/10.12775/QS.2025.48.67057Keywords
Bisphosphonates, MRONJ, osteoporosis, implantology, osteonecrosis of the jaw, antiresorptive drugs, peri-implantitis, osseointegrationAbstract
Introduction: Bisphosphonates and other antiresorptive drugs are the basis of pharmacotherapy for osteoporosis and cancerous diseases affecting the bones. Despite their high clinical efficacy, a growing number of scientific reports indicate a risk of osteonecrosis of the jaw (ONJ), especially in patients receiving intravenous and long-term treatment. Due to the increasing frequency of dental implant use and the延长ing average life expectancy of patients, the relationship between antiresorptive therapy and the success of implantation has become an important clinical issue. Understanding the mechanisms of ONJ development, risk factors, and current treatment guidelines is crucial to ensuring the safety of patients undergoing implant procedures.
Purpose of work: The aim of this paper is to present the current state of knowledge on the relationship between bisphosphonate therapy for osteoporosis and the risk of osteonecrosis of the jaw in the context of implant procedures. The study aims to discuss the mechanisms of action of bisphosphonates, factors predisposing to MRONJ, clinical course and treatment principles, as well as to review current recommendations for patient eligibility for implant procedures.
Materials and methods: An analysis of research papers available on PubMed and Google Scholar was undertaken using the following keywords: bisphosphonates; osteoporosis; MRONJ; medication-related osteonecrosis of the jaw; osteonecrosis; jawbone necrosis; antiresorptive therapy; dental implants; implantology; osseointegration.
Results: Analysis of current research confirms that the use of bisphosphonates, especially in intravenous form and in long-term therapy, significantly increases the risk of developing osteonecrosis of the jaw (ONJ), which may affect the success of dental implantation. In patients treated orally, this risk is lower, but not completely eliminated, especially after several years of therapy. The highest number of implant failures was reported in the lateral segments of the mandible and maxilla and in patients with existing inflammation, such as peri-implantitis, which may be a factor initiating MRONJ. Most studies indicate that implantation in patients taking oral bisphosphonates is possible but requires individual risk assessment and close monitoring. In patients treated with intravenous bisphosphonates, implantation is associated with a significantly higher risk of complications.
References
1. Consensus Development Conference (1993) Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650. Doi: 10.1016/0002-9343(93)90218-e
2. World Health Organization(1994)Assessment offracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129. Doi: 10.1007/BF01622200
3. Kanis JA on behalf of the WHO Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. WHO Collaborating Centre, University of Sheffield, Sheffield, UK, Technical Report
4. Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J, Eisman J (1993) Prediction of osteoporotic fractures by postural instability and bone density. BMJ 307:1111–1115. Doi: 10.1136/bmj.307.6912.1111
5. Kanis JA, Johnell O, Odén A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of oste oporotic fracture in Malmo. Osteoporos Int 11:669–674. Doi: 10.1007/s001980070064
6. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43. Doi: 10.1056/NEJM199511303332201
7. Pols HA, Felsenberg D, Hanley, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461-8. Doi: 10.1007/pl00004171
8. Black DM, Tompson DE, Bauer DC, et al. For FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-24. Doi: 10.1210/jcem.85.11.6953
9. Cranney A, Wells G, Wilian A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Res 2002; 23: 508-16. Doi: 10.1210/er.2001-2002
10. Bone HG, Adami SA, Rizzoli R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22: 15-28. Doi: 10.1016/s0149-2918(00)87974-6
11. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-60. Doi: 10.1185/030079905X61875
12. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9. Doi: 10.1359/JBMR.040325
13. Miller PD, Shergy WJ, Body JJ, et al. Long-term reduction of back pain in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 2005; 32: 1556-62
14. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100. Doi: 10.1210/edrv.19.1.0325
15. Ott SM. Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res 1993; 8 Suppl. 2: S597-S606. Doi: 10.1002/jbmr.5650081329
16. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004; 15: 423-33. Doi: 10.1007/s00198-004-1612-7
17. Chirurgia Stomatologiczna i Szczękowo-Twarzowa, red. Rahnama M, Tom 1, PZWL, Warszawa 2024.
18. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws [published correction appears in Ann Intern Med. 2006; 145(3):235]. Ann Intern Med. 2006;144(10):753-761. Doi: 10.7326/0003-4819-144-10-200605160-00009
19. Bilezikian JP. Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med. 2006;355(22):2278-2281. Doi: 10.1056/NEJMp068157
20. Black DM, Delmas PD, Eastell R, et al, HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. Doi: 10.1056/NEJMoa067312
21. Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget’s disease of bone. Bone. 2006 Oct;39(4):954-958. Epub 2006 Jun 12. Doi: 10.1016/j.bone.2006.04.032
22. Hewitt RE, Lissina A, Green AE, et al. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol. 2005; 139(1):101-111. Doi: 10.1111/j.1365-2249.2005.02665.x
23. Burr DB, Miller L, Grynpas M, et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone. 2003;33(6):960-969. Doi: 10.1016/j.bone.2003.08.004
24. US Food and Drug Administration. Information on bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). January 7, 2008. http://ovha.vermont.gov/forproviders/i3a_fda_gov_cder_drug_infopage_bisphosphonates_default.pdf. Accessed September 18, 2025.
25. Kunihara T, Tohmori H, Tsukamoto M, Kobayashi, M, Okumura T, Teramoto H, Hamasaki T, Yamasaki T, Nakagawa T, Okimoto N, et al. Incidence and trend of antiresorptive agent-related osteonecrosis of the jaw from 2016 to 2020 in Kure, Japan. Osteoporos. Int. 2023, 34, 1101–1109. Doi: 10.1007/s00198-023-06732-8
26. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J. Clin. Oncol. 2003, 21, 4253–4254. Doi: 10.1200/JCO.2003.99.132
27. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J. Oral Maxillofac. Surg. 2004, 62, 527–534. Doi: 10.1016/j.joms.2004.02.004
28. Marx .E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 2003, 61, 1115–1117. Doi: 10.1016/s0278-2391(03)00720-1
29. Podstawy Chirurgii Stomatologicznej, Dominiak M,Gedrange T, Rahnama M, wyd. 3, Edra Urban & Partner, Wrocław 2022
30. Miranda-Silva W, Montezuma MA, Benites BM, Bruno JS, Fonseca FP, Fregnani ER. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support Care Cancer 2020, 28, 5397–5404. Doi: 10.1007/s00520-020-05374-4
31. Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med. J. 2011, 32, 830–835.
32. Veitz-Keenan A, Keenan JR. Implant outcomes poorer in patients with history of periodontal disease. Evid.-Based Dent. 2017, 18,5. Doi: 10.1038/sj.ebd.6401214
33. European Federation of Periodontology Home Page. Available online: https://www.efp.org/faqs/#:~:text=Implants%20are%20 also%20not%20suitable,tissue)%20develops%20suddenly%20and%20quickly (accessed on 24 September 2025).
34. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update. J. Oral Maxillofac. Surg. 2022, 80, 920–943. Doi: 10.1016/j.joms.2022.02.008
35. Guidance on the Standards of Care for NHS-Funded Dental Implant Treatment 2019; Royal College of Surgeons of England Faculty of Dentistry: London, UK, 2019.
36. 43. Nisi M, La Ferla F, Karapetsa D, et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg 2015;44:586–91. Doi: 10.1016/j.ijom.2015.01.014
37. Giovannacci I, Meleti M, Manfredi M, et al. Medication-related osteonecrosis of the jaw around dental implants: implant surgerytriggered or implant presence-triggered osteonecrosis? J Craniofac Surg 2016;27:697–701. Doi: 10.1097/SCS.0000000000002564
38. Tallarico M, Canullo L, Xhanari E, et al. Dental implants treatment outcomesin patient under active therapy with alendronate: 3-year followup results of a multicenter prospective observational study. Clin Oral Implants Res 2016;27:943–9. Doi: 10.1111/clr.12662
39. Holzinger D, Seemann R, Matoni N, et al. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2014;72, 1937 e1-8. Doi: 10.1016/j.joms.2014.04.037
40. Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014;25:632–40. Doi: 10.1111/clr.12088
41. Troeltzsch M, Cagna D, Stahler P, et al. Clinical features of peri-implant medication-related osteonecrosis of the jaw: is there an association to peri-implantitis? J Craniomaxillofac Surg 2016;44:1945–51. Doi: 10.1016/j.jcms.2016.09.018
42. Ata-Ali J, Ata-Ali F, Penarrocha-Oltra D, et al. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 2016;27:e38–46. Doi: 10.1111/clr.12526
43. Fugazzotto PA, Lightfoot WS, Jaffin R, et al. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol 2007;78:1664–9. Doi: 10.1902/jop.2007.060514
44. Goss ADF, Bartold MDF, Sambrook PMBBSF, Hawker PBDSMS. The Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Dental Implant Patients: A South Australian Case Series. J. Oral Maxillofac. Surg. 2010, 68, 337–343. Doi: 10.1016/j.joms.2009.09.037
45. Massaad J, Magremanne M. Is medication related osteonecrosis of the jaw around implants a rare entity? A case series with a focus on etiopathophysiology. J. Stomatol. Oral Maxillofac. Surg. 2022, 123, e743–e748. Doi: 10.1016/j.jormas.2021.12.002
46. Jacobsen C, Metzler P, Rössle M, Obwegeser J, Zemann W, Grätz KW. Osteopathology induced by bisphosphonates and dental implants: Clinical observations. Clin. Oral Investig. 2013, 17, 167–175. Doi: 10.1007/s00784-012-0708-2
47. Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants. J. Oral Maxillofac. Surg. 2010, 68, 790–796. Doi: 10.1016/j.joms.2009.09.017
48. Seki K, Namaki S, Kamimoto A, Hagiwara Y. Medication-Related Osteonecrosis of the Jaw Subsequent to Peri-Implantitis: A Case Report and Literature Review. J. Oral Implantol. 2021, 47, 502–510. Doi: 10.1563/aaid-joi-D-19-00385
49. Tempesta A, Capodiferro S, Mauceri R, Lauritano D, Maiorano E, Favia G, Limongelli L. Peri-implantitis-like medicationrelated osteonecrosis of the jaw: Clinical considerations and histological evaluation with confocal laser scanning microscope. Oral Dis. 2022, 28, 1603–1609. Doi: 10.1111/odi.13873
50. Pogrel MA, Ruggiero SL. Previously successful dental implants can fail when patients commence anti-resorptive therapy—A case series. Int. J. Oral Maxillofac. Surg. 2018, 47, 220–222. Doi: 10.1016/j.ijom.2017.07.012
51. Kün-Darbois JD, Fauvel F: Medication-related osteonecrosis and osteoradionecrosis of the jaws: update and current management. Morphologie. 2021, 105:170-87. Doi: 10.1016/j.morpho.2020.11.008
52. Rebelo CG, Fernandes JC, Bernardo N, Couto P, Fernandes GV: Bisphosphonates and their influence on the implant failure: a systematic review. Appl Sci. 2023, 13:3496. Doi: 10.3390/app13063496
53. Anitua E, Alkhraisat M, Eguia A: Clinical performance of implant-supported prostheses in the rehabilitation of patients previously treated for medication-related osteonecrosis of the jaws (MRONJ): a systematic review. Cureus. 2024, 16:e61658. Doi: 10.7759/cureus.61658
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Natalia Tarczyńska, Szymon Górski, Joanna Okupniarek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 3
Number of citations: 0
